Skip to main content

Search Results

Displaying: 1 - 10 of 13 Results

Continuous directed evolution of aminoacyl-tRNA synthetases to alter amino acid specificity and enhance activity

DESCRIPTION Functions of various biotherapeutics can often be enhanced by modifying individual amino acid residues. However, the current approaches rely on existing natural amino acid chemistry. Approaches that provide new chemical “handles” will…

Investigators

  • David Liu

Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers

DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…

Investigators

  • David Liu

Oral delivery of biologics

Biologics are used to treat a variety of chronic diseases including diabetes and arthritis. Not surprisingly, they command a large share of the therapeutics market. Moreover, a large number of therapeutic proteins are currently in clinical…

Investigators

  • Samir Mitragotri

aP2 knock-out mice

AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…

Investigators

  • Gokhan Hotamisligil

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…

Investigators

  • David Liu
  • Juan Pablo Maianti

The next generation of cholesterol screening - A personalized diagnostic index for the improved assessment of cardiovascular risk using a novel method for the measurement of lipoprotein subtypes

OpportunityThis program offers the next generation of cholesterol screening. In 2013, 96 million visits to doctors' offices in the US included a cholesterol test.Problem/Unmet needCurrent practice of measuring total HDL level in serum does not…

Investigators

  • Frank Sacks

Potent OGT inhibitors for the treatment of cancer and diabetic complications

First-in-class and potent OGT inhibitors The Walker group has developed novel high throughput assays (HTS) and screened 200,000 compounds at the Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School, and identified several…

Investigators

  • Suzanne Walker Kahne
  • Michael Lazarus
  • Benjamin Gross

Novel lipid hormone for identifying and treating metabolic disease

Scientists in the Harvard School of Public Health have identified fatty acid C16:1n7-palmitoleate, a novel signaling lipid produced by adipose tissue, that protects mice from the detrimental effects of long-term consumption of high-fat diets. They…

Investigators

  • Gokhan Hotamisligil
  • Dariush Mozaffarian
  • Haiming Cao

Cyborg tissue: Macroporous nanowire nanoelectronic scaffolds for synthetic tissues

This technology uses macroporous, flexible and free-standing nanowire nanoelectronic scaffolds (nanoES), and their hybrids with synthetic or natural biomaterials. 3D macroporous nanoES mimic the structure of natural tissue scaffolds. The structures…

Investigators

  • Charles Lieber
  • Bozhi Tian
  • Jia Liu

Targeted inhibition of the SREBP-mediator interaction as a novel therapeutic

While most therapeutic approaches aimed at altering gene expression programs target upstream signaling pathways or nuclear translocation checkpoints, Scientists at the Wagner lab have provided mechanistic insights supporting an alternative approach,…

Investigators

  • Gerhard Wagner
  • Anders Naar
  • Haribabu Arthanari

Page 1 of 2